7例t(11;19)(q23;p13)急性髓系白血病临床分析并文献复习  

Clinical analysis of 7 cases of acute myeloid leukemia t(11;19)(q23;p13)and review of literatures

作　　者：陈英毅 赵宇 柏岸波 胡杰英 高绍冰 CHEN Yingyi;ZHAO Yu;BAI Anbo;HU Jieying;GAO Shaobing(Central Laboratory,the Affiliated Cancer Hospital of Zhengzhou University(Henan Cancer Hospital),Henan Zhengzhou 450008,China)

机构地区：[1]郑州大学附属肿瘤医院(河南省肿瘤医院)中心实验室,河南郑州450008

出　　处：《现代肿瘤医学》2024年第22期4355-4358,共4页Journal of Modern Oncology

基　　金：河南省重点研发与推广专项(科技攻关)项目(编号:222102310579)。

摘　　要：目的:分析7例伴t(11;19)(q23;p13)急性髓系白血病(acute myeloid leukemia,AML)患者的临床特点和预后。方法:纳入2018年03月至2022年06月我院收治的7例伴t(11;19)(q23;p13)染色体异常的AML患者,回顾性分析一般临床资料、染色体核型、融合基因、细胞免疫分型、治疗方案及疗效,并进行相关文献复习。结果:7例AML患者的FAB分型为4例AML-M4、3例AML-M5,初诊时均伴KMT2A-ELL融合基因阳性;免疫分型为7例患者均表达HLA-DR、CD13、CD33、CD38,其中6例表达CD117,符合髓系抗原特征;7例患者均进行化疗,其中6例化疗后行异体造血干细胞移植(allogeneic hematopoietic stem cell transplantation,allo-HSCT);截至2023年12月21日随访结束,7例患者中5例死亡,仅2例存活,中位总生存期为9(3~69)个月。结论:t(11;19)(q23;p13)为血液系统恶性肿瘤中少见的染色体易位,多发生于急性髓系白血病患者中,预后差。Objective:To analyze the clinical characteristics and prognosis of 7 acute myeloid leukemia(AML)patients with t(11;19)(q23;p13).Methods:7 cases of t(11;19)(q23;p13)AML patients in our hospital from March 2018 to June 2022 were included to review clinical data,chromosome karyotyping,fusion gene,immunophenotype,treatment regimen and efficacy,with review of related literatures.Results:FAB type of 7 AML patients:4 cases of AML-M4 and 3 cases of AML-M5,all with KMT2A-ELL fusion gene positive at initial diagnosis.Immunophenotype:All the 7 patients expressed HLA-DR,CD13,CD33,CD38,while 6 patients expressed CD117,which was consistent with the characteristics of myeloid antigens.All the 7 patients received chemotherapy,and 6 of them received allogeneic hematopoietic stem cell transplantation(allo-HSCT)after chemotherapy.By the end of the follow-up on December 21,2023,five of the seven patients died and only two surviving,with a median overall survival of 9(3~69)months.Conclusion:The t(11;19)(q23;p13)abnormality is one of the rare chromosomal translocations in hematological malignancies that is found mostly in acute myeloid leukemia with a poor prognosis.

关 键 词：急性髓系白血病 t(11 19)(q23 p13) KMT2A-ELL 

分 类 号：R730.5[医药卫生—肿瘤]